



Cancer Prevention and Control CIRB Meeting Agenda

July 27, 2023

I. Initial Review

EAQ223, The ECOG-ACRIN SUPPORT Trial: Multilevel Intervention to Improve Diverse Enrollment in Cancer Clinical Trials (Version Date 05/12/23)

II. Initial Review

UAZ22-11-01, Phase II Randomized, Double-Blind, Placebo-Controlled, Crossover Trial of Broccoli Seed and Sprout Extract (BSSE) to Evaluate Detoxification of Carcinogens in Firefighters (Version Date 05/31/23)

III. Initial ReReview

A212101, Evaluation of Provider vs. Patient Mediated Cascade Genetic Testing of First-Degree Relatives of Patients with Newly Diagnosed Colorectal Cancer (Version Date 07/12/23)

IV. Amendment Prior to Activation

UWI20-04-01, A Dose Escalation Phase I Trial of the Safety and Immunogenicity of RG1-VLP, a Candidate Broadly Protective Vaccine for the Prevention of HPV-Associated Cancer (Version Date 05/02/23)

V. Continuing Review

EAZ171, Prospective validation trial of taxane therapy (docetaxel or weekly paclitaxel) and risk of chemotherapy-induced peripheral neuropathy in African American women (Version Date 02/26/21)

VI. Continuing Review

S1912CD, A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT) (Version Date 06/07/23)

VII. Potential Unanticipated Problem or Serious/Continuing Non-Compliance Review #1

INT21-05-01, A Phase IIB Clinical Trial of the Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury) Vaccine (TRI-AD5) and IL-15 Superagonist N-803 in Lynch Syndrome (Version Date 02/09/23)

VIII. Potential Unanticipated Problem or Serious/Continuing Non-Compliance Review #2

INT21-05-01, A Phase IIB Clinical Trial of the Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury) Vaccine (TRI-AD5) and IL-15 Superagonist N-803 in Lynch Syndrome (Version Date 02/09/23)

IX. Potential Unanticipated Problem or Serious/Continuing Non-Compliance Review

URCC-16070, Treatment of Refractory Nausea (Version Date 01/04/23)

X. Potential Unanticipated Problem or Serious/Continuing Non-Compliance Review

UWI20-00-01, A Phase II Trial of the Immunogenicity of a DNA Plasmid Based Vaccine (STEMVAC) Encoding Th1 Selective Epitopes from Five Antigens Associated With Breast Cancer Stem Cells (MDM2, YB1, SOX2, CDH3, CD105) in Participants with Triple Negative Breast Cancer (Version Date 06/30/23)

XI. Continuing Review

URCC-19075, Multi-center Randomized Controlled Phase II Trial of Exercise to Treat Chemotherapy-Induced Peripheral Neuropathy (CIPN) (Version Date 03/25/22)

XII. Continuing Review

WF-1801, A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy (Version Date 10/25/22)

XIII. Continuing Review

WF-97415, Understanding and Predicting Breast Cancer Events after Treatment (UPBEAT) (Version Date 04/08/22)
